Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. A Meta-Analysis

Journal of the American College of Cardiology

Volumn 49, Issue 20, 2007, Pages 2003-2009

  Kinlay, Scott ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; EZETIMIBE; FENOFIBRATE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 34248342266     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.01.083     Document Type: Article

References (70)

1. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94 (1996) 2013-2020
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
3. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
4. Blake G.J., Rifai N., Buring J.E., and Ridker P.M. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108 (2003) 2993-2999
5. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
6. van der Meer I.M., de Maat M.P., Kiliaan A.J., van der Kuip D.A., Hofman A., and Witteman J.C. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163 (2003) 1323-1328
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (see comments). N Engl J Med 339 (1998) 1349-1357
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
10. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
11. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
12. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
13. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
14. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
15. Kinlay S., Libby P., and Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 12 (2001) 383-389
16. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 (2003) 670-682
17. Follmann D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45 (1992) 769-773
18. Bays H.E., Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
19. Goldberg A.C., Sapre A., Liu J., Capece R., and Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79 (2004) 620-629
20. Jenkins D.J., Kendall C.W., Faulkner D., et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51 (2002) 1596-1604
21. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
22. Bogaty P., Dagenais G.R., Poirier P., et al. Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 92 (2003) 1192-1195
23. Crea F., Monaco C., Lanza G.A., et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin Cardiol 25 (2002) 461-466
24. Gomez-Gerique J.A., Ros E., Olivan J., et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 162 (2002) 245-251
25. Joukhadar C., Klein N., Prinz M., et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 85 (2001) 47-51
26. Lu T.M., Ding Y.A., Leu H.B., Yin W.H., Sheu W.H., and Chu K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 94 (2004) 157-161
27. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
28. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
29. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
30. Sommeijer D.W., MacGillavry M.R., Meijers J.C., Van Zanten A.P., Reitsma P.H., and Ten Cate H. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27 (2004) 468-473
31. van Wissen S., Trip M.D., Smilde T.J., de Graaf J., Stalenhoef A.F., and Kastelein J.J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165 (2002) 361-366
32. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., and Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
33. Wieland E., Schettler V., and Armstrong V.W. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis 162 (2002) 187-191
34. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
35. Balletshofer B.M., Goebbel S., Rittig K., et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2 diabetes-a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 113 (2005) 324-330
36. Chan D.C., Watts G.F., Barrett P.H., Beilin L.J., and Mori T.A. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 48 (2002) 877-883
37. Chang J.W., Yang W.S., Min W.K., Lee S.K., Park J.S., and Kim S.B. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 (2002) 1213-1217
38. Costa A., Casamitjana R., Casals E., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 20 (2003) 743-745
39. Economides P.A., Caselli A., Tiani E., Khaodhiar L., Horton E.S., and Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 740-747
40. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 162 (2002) 1568-1576
41. Jenkins D.J., Kendall C.W., Marchie A., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290 (2003) 502-510
42. Kalela A., Laaksonen R., Lehtimaki T., et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 88 (2001) 173-175
43. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
44. Miller M., and Jialal I. Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Am J Cardiol 89 (2002) 468-469
45. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., and Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
46. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
47. Sager P.T., Melani L., Lipka L., et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92 (2003) 1414-1418
48. Solheim S., Seljeflot I., Arnesen H., Eritsland J., and Eikvar L. Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157 (2001) 411-415
49. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., and Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87 (2002) 563-568
50. van de Ree M.A., Huisman M.V., Princen H.M., Meinders A.E., and Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135
51. Ballantyne C.M., Abate N., Yuan Z., King T.R., and Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 149 (2005) 464-473
52. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
53. Kinlay S., Timms T., Clark M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89 (2002) 1205-1207
54. Li J.J., Chen M.Z., Chen X., and Fang C.H. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 26 (2003) 472-476
55. Milionis H.J., Kakafika A.I., Tsouli S.G., et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148 (2004) 635-640
56. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
57. Stein E.A., Strutt K., Southworth H., Diggle P.J., and Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 92 (2003) 1287-1293
58. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., and Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
59. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-742
60. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998) 2433-2444
61. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
62. Aikawa M., Sugiyama S., Hill C.C., et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106 (2002) 1390-1396
63. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
64. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
65. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?. A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
66. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47 (2001) 444-450
67. Bogaty P., Brophy J.M., Boyer L., et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 165 (2005) 221-226
68. Riesen W.F., Engler H., Risch M., Korte W., and Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23 (2002) 794-799
69. Strandberg T.E., Vanhanen H., and Tikkanen M.J. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 32 (2000) 579-583
70. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297